Advertisement

Clinical Pharmacokinetics

, Volume 45, Issue 2, pp 214–215 | Cite as

The Authors’ Reply

  • Alwin D. R. Huitema
  • Jos H. Beijnen
Correspondence
  • 14 Downloads

Keywords

Efavirenz Virological Failure Population Pharmacokinetic Interpatient Variability Immune Recovery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kappelhoff BS, Huitema ADR, Yalvac Z, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005; 44(8): 849–61PubMedCrossRefGoogle Scholar
  2. 2.
    Crommentuyn KML, Kappelhoff BS, Mulder JW, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1 infected patients. Br J Clin Pharmacol 2005; 60: 378–89PubMedCrossRefGoogle Scholar
  3. 3.
    Kappelhoff BS, Huitema ADR, Sankatsing SU, et al. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1 infected patients. Br J Clin Pharmacol 2005; 60: 276–86PubMedCrossRefGoogle Scholar
  4. 4.
    Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Swiss HIV cohort study. Pharmacogenet Genomics 2005; 15: 1–5PubMedCrossRefGoogle Scholar
  5. 5.
    Haas DW. Will pharmacogenomic discoveries improve HIV therapeutics?. Topics in HIV Medicine 2005; 13: 90–5PubMedGoogle Scholar
  6. 6.
    Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Swiss HIV Cohort Study. Lancet 2002; 359: 30–6PubMedCrossRefGoogle Scholar
  7. 7.
    Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391–400PubMedGoogle Scholar
  8. 8.
    Hasse B, Gunthard HF, Bleiber G, et al. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 2005; 40: E22–3PubMedCrossRefGoogle Scholar
  9. 9.
    Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40: 1358–61PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Alwin D. R. Huitema
    • 1
  • Jos H. Beijnen
    • 1
  1. 1.Department of Pharmacy and PharmacologySlotervaart HospitalAmsterdamThe Netherlands

Personalised recommendations